🇺🇸 FDA
Pipeline program

ETC-1002

1002-005

Phase 2 small_molecule completed

Quick answer

ETC-1002 for Hyperlipidemia is a Phase 2 program (small_molecule) at Esperion Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Esperion Therapeutics
Indication
Hyperlipidemia
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials